Medicare Enrolled
Dr. Rasha Beg, M.D.
Medical Oncology · Amarillo, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Beg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Beg? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Beg
Dr. Rasha Beg is a medical oncology in Amarillo, TX, with 18 years in practice. Based on federal Medicare data, Dr. Beg performed 20,312 Medicare services across 1,302 unique beneficiaries.
Between the years covered by Open Payments, Dr. Beg received a total of $14,407 from 90 pharmaceutical and/or device companies across 655 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Beg is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 35% volume in TX$ $14,407 industry payments
Medicare Practice Summary
Medicare Utilization ↗20,312
Medicare services
Top 35% in TX for medical oncology
1,302
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,128 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 14,790 | $0 | $4 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $18 | $51 |
| Complete blood count (CBC) with differential | 544 | $8 | $29 |
| Dexamethasone injection (steroid) | 480 | $0 | $3 |
| Blood draw (venipuncture) | 472 | $8 | $9 |
| Office visit, established patient (30-39 min) | 275 | $87 | $343 |
| Anti-nausea injection (ondansetron/Zofran) | 256 | $0 | $9 |
| Drug injection, under skin or into muscle | 218 | $9 | $69 |
| Injection of additional new drug or substance into vein | 116 | $12 | $61 |
| Office visit, established patient (20-29 min) | 99 | $63 | $242 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 81 | $1 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 79 | $97 | $378 |
| Hospital follow-up visit, moderate complexity | 73 | $63 | $219 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 70 | $46 | $189 |
| New patient office visit (45-59 min) | 61 | $111 | $476 |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $21 | $84 |
| Initial hospital admission, moderate complexity | 40 | $102 | $381 |
| Injection of drug or substance into vein | 32 | $25 | $156 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 25 | $3 | $11 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $16 | $59 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 14 | $66 | $277 |
| New patient office visit (30-44 min) | 11 | $88 | $302 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
73.4% high complexity
18.7% medium
7.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,407
Total received (2018-2024)
Avg $2,058/year across 7 years
Top 34% in TX for medical oncology
90
Companies
655
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,084 (83.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,323 (16.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,018
2023$2,045
2022$2,963
2021$2,109
2020$1,599
2019$1,980
2018$693
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Ipsen Biopharmaceuticals, Inc
$1,906
Novartis Pharmaceuticals Corporation
$1,212
Janssen Biotech, Inc.
$1,030
E.R. Squibb & Sons, L.L.C.
$741
Amgen Inc.
$659
PFIZER INC.
$562
Genentech USA, Inc.
$561
GENZYME CORPORATION
$542
Daiichi Sankyo Inc.
$519
Celgene Corporation
$470
AstraZeneca Pharmaceuticals LP
$468
Lilly USA, LLC
$326
SOBI, INC
$323
Bayer HealthCare Pharmaceuticals Inc.
$299
Seagen Inc.
$277
Pharmacyclics LLC, An AbbVie Company
$264
Merck Sharp & Dohme Corporation
$252
Eisai Inc.
$242
GlaxoSmithKline, LLC.
$227
Astellas Pharma US Inc
$226
Boehringer Ingelheim Pharmaceuticals, Inc.
$212
BeiGene USA, Inc.
$205
Incyte Corporation
$204
EISAI INC.
$165
Clovis Oncology, Inc.
$153
Merck Sharp & Dohme LLC
$116
AMAG Pharmaceuticals, Inc.
$110
ARRAY BIOPHARMA INC
$95
SANOFI-AVENTIS U.S. LLC
$91
Alexion Pharmaceuticals, Inc.
$87
Regeneron Healthcare Solutions, Inc.
$83
Karyopharm Therapeutics Inc.
$82
ABBVIE INC.
$81
Pharmacosmos Therapeutics Inc.
$75
Puma Biotechnology, Inc.
$71
Gilead Sciences, Inc.
$68
Foundation Medicine, Inc.
$68
PharmaEssentia USA Corporation
$66
Tempus AI, Inc
$56
Stemline Therapeutics Inc.
$55
Global Blood Therapeutics, Inc.
$50
Emmaus Medical, Inc.
$43
TerSera Therapeutics LLC
$42
Pharmacyclics LLC, an AbbVie Company
$41
Dendreon Pharmaceuticals LLC
$40
Servier Pharmaceuticals LLC
$39
PUMA BIOTECHNOLOGY, INC.
$37
Taiho Oncology, Inc.
$37
MorphoSys, US Inc.
$36
SECURA BIO, INC.
$36
Adaptive Biotechnologies Corporation
$35
Kyowa Kirin, Inc.
$34
Lexicon Pharmaceuticals, Inc.
$34
Seattle Genetics, Inc.
$33
TAIHO ONCOLOGY, INC.
$31
INSYS Therapeutics Inc
$29
Sumitomo Pharma America, Inc.
$27
ADC Therapeutics America, Inc.
$25
Alnylam Pharmaceuticals Inc.
$25
Acrotech Biopharma LLC
$24
Coherus Biosciences Inc.
$23
AbbVie Inc.
$23
Mirati Therapeutics, Inc.
$22
Menarini Silicon Biosystems, Inc.
$22
Apellis Pharmaceuticals, Inc.
$21
Takeda Pharmaceuticals U.S.A., Inc.
$20
Deciphera Pharmaceuticals Inc.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$19
Tolmar, Inc.
$18
Array BioPharma Inc.
$17
Bayer Healthcare Pharmaceuticals Inc.
$17
CTI BioPharma Corp.
$17
Sobi, Inc
$17
Kite Pharma, Inc.
$16
JAZZ PHARMACEUTICALS INC.
$16
Blueprint Medicines Corporation
$16
Heron Therapeutics, Inc.
$15
Dova Pharmaceuticals
$15
AbbVie, Inc.
$14
Partner Therapeutics, Inc.
$13
G1 Therapeutics, Inc.
$13
Spectrum Pharmaceuticals Inc.
$13
NanoString Technologies, Inc.
$12
MEDIVATION FIELD SOLUTIONS LLC
$12
Janssen Pharmaceuticals, Inc
$12
Agios Pharmaceuticals, Inc.
$12
West Therapeutics Development, LLC
$11
Secura Bio, Inc.
$8
Fortovia Therapeutics, Inc.
$6
Veracyte, Inc.
$2
Top 3 companies account for 28.8% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · Alecensa · Aliqopa · Avastin · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABLIVI · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Cellsearch · Columvi · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Endari · Enhertu · Erleada · FERAHEME · FOUNDATIONONE · Fabhalta · Farydak · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · Inrebic · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LYNPARZA · Lazanda · Lenvima · Leukine · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSIGNA ASSAY · PROVENGE · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Rituxan · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Stivarga · Sustol · TASIGNA · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tazverik · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $71 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
3.4
County median income
$50,448
Nearest hospital
NORTHWEST TEXAS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Beg is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Beg experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Beg performed 14,790 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Beg receive payments from pharmaceutical companies?
Yes. Dr. Beg received a total of $14,407 from 90 companies across 655 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Beg's costs compare to other medical oncologys in Amarillo?
Dr. Beg's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Beg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Amarillo
Browse medical oncologys in Amarillo ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Ipsen Biopharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Ipsen Biopharmaceuticals, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology